These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3495987)

  • 1. Pulmonary complications of cytosine-arabinoside therapy: radiographic findings.
    Tham RT; Peters WG; de Bruïne FT; Willemze R
    AJR Am J Roentgenol; 1987 Jul; 149(1):23-7. PubMed ID: 3495987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
    Willemze R; Jager U; Jehn U; Stryckmans P; Bury J; Suciu S; Solbu G; Zittoun R; Burghouts J; Löwenberg B
    Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1721-5. PubMed ID: 3061827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
    Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.
    Willemze R; Peters WG; van Hennik MB; Fibbe WE; Kootte AM; van Berkel M; Lie R; Rodenburg CJ; Veltkamp JJ
    Scand J Haematol; 1985 Jan; 34(1):83-7. PubMed ID: 3855571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma.
    Willemze R; Zijlmans JM; den Ottolander GJ; Kluin-Nelemans JC; Falkenburg JH; Starrenburg CW; van der Burgh JF; Fibbe WE
    Ann Hematol; 1995 Feb; 70(2):71-4. PubMed ID: 7880926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
    Zittoun R; Marie JP; Zittoun J; Marquet J; Haanen C
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):139-43. PubMed ID: 3859928
    [No Abstract]   [Full Text] [Related]  

  • 10. Intermediate and high-dose cytosine arabinoside-containing regimens for induction and consolidation therapy for patients with acute lymphoblastic leukemia and lymphoblastic non-Hodgkin's lymphoma: the Leyden experience and review of the literature.
    Peters WG; Willemze R; Colly LP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):86-91. PubMed ID: 3473687
    [No Abstract]   [Full Text] [Related]  

  • 11. Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy.
    Whelan JS; Davis CL; Rohatiner AZ; Leahy M; MacCallum PK; Gupta RK; Matthews J; Norton AJ; Amess JA; Lister TA
    Hematol Oncol; 1992; 10(2):87-94. PubMed ID: 1592366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
    Koyama S; Itou S; Shibata A
    Rinsho Ketsueki; 1990 Nov; 31(11):1891-2. PubMed ID: 2287079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
    Peters WG; Willemze R; Colly LP
    Eur J Haematol; 1988 Mar; 40(3):198-204. PubMed ID: 3162718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
    Dekker AW; Nieuwenhuis HK; Verdonck LF
    Cancer; 1990 May; 65(9):1891-4. PubMed ID: 2372760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose cytosine arabinoside as consolidation chemotherapy for acute nonlymphocytic leukemia in remission.
    Urabe A; Mizoguchi H; Hoshino S; Nomura T; Dan K; Toyama K; Kimura M; Ogawa T; Yamaguchi H; Mutoh Y
    Int J Hematol; 1991 Feb; 54(1):75-7. PubMed ID: 1954354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary results of consolidation therapy with high-dose cytosine arabinoside for patients with bad-risk or relapsed acute leukemia or lymphoblastic non-Hodgkin's lymphoma.
    Peters WG; Willemze R; Colly LP
    Eur J Cancer Clin Oncol; 1987 Apr; 23(4):401-5. PubMed ID: 3609104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytosine arabinoside for induction, salvage, and consolidation therapy of adult acute lymphoblastic leukemia.
    Stryckmans P; De Witte T; Bitar N; Marie JP; Suciu S; Solbu G; Debusscher L; Bury J; Peetermans M; Andrien JM
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):67-72. PubMed ID: 3296209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
    Chen YC; Lin SF; Yao M; Chen TY; Tsao CJ; Chen TP
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):30-4. PubMed ID: 8916314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sequential combination of high-dose cytosine arabinoside and L-asparaginase in the treatment of refractory acute leukemia and malignant lymphoma].
    Shimazaki C; Fujita N; Nakanishi S; Nishio A; Haruyama H; Nakagawa M; Ijichi H
    Gan To Kagaku Ryoho; 1985 Nov; 12(11):2202-7. PubMed ID: 3864396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.